Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Cancer Lett. 2020 Feb 27;477:97–106. doi: 10.1016/j.canlet.2020.02.025

Figure 5: Radiogenomics map demarcating regions of amplification (amp) for Epidermal Growth Factor Receptor (EGFR) in a 67 y/o Male with primary GBM.

Figure 5:

(A) The lesion is shown on the T2W image, with the margins demarcated by the bright green outline. The location of the biopsy (which was subsequently genetically profiled) is shown by the yellow arrow and yellow circle. (B) The central enhancing component is outlined by the dark green line on the T1+C image. The biopsy location (yellow arrow, yellow circle) is again shown, originating from the T1+C enhancing component of tumor. (C) The radiogenomics map shows predicted regions of EGFR amplification (red) and non-amplified wildtype (wt) (blue), throughout the entire T2W region of interest (bright green outline). The radiogenomics map prediction of EGFR wildtype (blue) for the biopsy location corresponds with the low copy number variant (CNV) of 2.89 for EGFR, consistent with absence of amplification.